SNGX: Soligenix Quarterly EPS earnings growth

Public company logo of Soligenix (SNGX)

The quarterly EPS change demonstrates volatility due to reliance on component supplies from Asia and logistical risks, with the latest value recorded as 91.20. Soligenix, Inc. revenues are based on government contracts for biodefense and lymphoma treatment. The development strategy relies on the independent promotion of drugs and securing grants without pursuing external acquisitions to preserve capital.

Soligenix Inc (SNGX) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/13/2026

Summary analytical data breakdowns for Soligenix, Inc. (SNGX)

- share price and expert price forecast:
Stock Price soligenix.com|SNGX - Forecast Levels Chart
- market capitalization information:
Market Capitalization BioPharma Bio|SNGX - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Soligenix|SNGX - Company Net Assets|Market Cap to Net Assets Ratio soligenix.com|SNGX - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Soligenix, Inc.|SNGX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity soligenix.com|SNGX - Company Cumulative Debt|Debt to Book Capitalization Ratio BioPharma Bio|SNGX - Company Long-Term Indebtedness|Company Short-Term Debt Soligenix|Quick Liquidity soligenix.com
- earnings and valuation multiples indicators:
SNGX - Net Financial Result|Expected Profit Soligenix, Inc.|SNGX - Market Cap to Earnings|Future Price to Earnings soligenix.com|SNGX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioPharma Bio|SNGX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Soligenix|SNGX - Net earnings per share for the trailing year|Quarterly EPS earnings growth soligenix.com|SNGX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Soligenix, Inc.
- revenue and sales proceeds data:
SNGX - Company Sales Volume|Projected Sales Volume soligenix.com|SNGX - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple BioPharma Bio
Comprehensive company analysis:Soligenix, Inc.
Flagship merchandise of soligenix.com

When screening assets, an investor assesses business resilience through net income per share dynamics, which measure capital generation efficiency relative to the volume of issuance. For Soligenix, Inc. (SNGX), this metric reflects the monetization of government contracts and niche drugs, allowing for the verification of the fundamental growth trend through the comparison of quarterly EPS regardless of price wars.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Corp TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months serestherapeutics.com MCRB|Spero Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months SCYX (SCYNEXIS Inc)|AN2 Bio - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months PolyPid Ltd. PYPD|LakeShore Biopharma Co. (LSB) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Iterum Therapeutics (ITRM)|Year-over-year earnings per share growth for the last twelve months BiomX Inc|Year-over-year earnings per share growth for the last 12 months SXTP (60 Degrees Pharma)|Year-over-year earnings per share growth for the last twelve months Oragenics, Inc. (OGEN)|Year-over-year net earnings per share change for the last twelve months OpGen Corporation